<SEC-DOCUMENT>0001826667-25-000115.txt : 20250812
<SEC-HEADER>0001826667-25-000115.hdr.sgml : 20250812
<ACCEPTANCE-DATETIME>20250812160333
ACCESSION NUMBER:		0001826667-25-000115
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250812
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250812
DATE AS OF CHANGE:		20250812

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TriSalus Life Sciences, Inc.
		CENTRAL INDEX KEY:			0001826667
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				853009869
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39813
		FILM NUMBER:		251206539

	BUSINESS ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031
		BUSINESS PHONE:		415 336 8917

	MAIL ADDRESS:	
		STREET 1:		6272 WEST 91ST AVENUE
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80031

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedTech Acquisition Corp
		DATE OF NAME CHANGE:	20200930
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tlsi-20250812.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:aedd4729-9990-4c3f-a3fb-d105919b6fed,g:4d950ad1-f782-4aff-baf4-8e324f289b63,d:e98fbc9c35d94056ad4d5c1d977615bb-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>tlsi-20250812</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0001826667</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-26">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="tlsi-20250812.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001826667</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-12</xbrli:startDate><xbrli:endDate>2025-08-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ie98fbc9c35d94056ad4d5c1d977615bb_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">Washington, D.C. 20549</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August&#160;12, 2025</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:139%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">TRISALUS LIFE SCIENCES, INC.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.688%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-39813</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">85-3009869</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:3.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="margin-bottom:1.5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">6272 W 91st Ave</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Westminster</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Colorado</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">80031</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">(888)</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:139%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%"><ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">321-5212</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> (Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.662%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.467%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17">Common stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-18">TLSI</ix:nonNumeric></span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">Nasdaq</ix:nonNumeric> Global Market</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-20">Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-21">TLSIW</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">Nasdaq</ix:nonNumeric> Global Market</span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:139%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-23">x</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 2.02</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations and Financial Conditions.</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;12, 2025, TriSalus Life Sciences, Inc. (the &#8220;Company&#8221;) issued a press release providing a business update and announcing its financial results for the quarter ended June&#160;30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#8217;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filings.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.912%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.252%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Item 9.01</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements and Exhibits.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="q22025earningsrelease.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Press Release dated August&#160;12, 2025</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.722%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Date: August&#160;12, 2025</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">TriSalus Life Sciences, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Patience</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">David Patience</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q22025earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2e400b2b03994483ad121dd14715ba19_1"></div><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TriSalus Life Sciences Second Quarter 2025 Results and Provides Updated 2025 Guidance</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company delivers </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.2M in revenues resulting in 52%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> growth year-over-year and 22% growth quarter-over-quarter</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%">Broadened PEDD portfolio with launch of TriNav FLX designed to improve access in tortuous vessels</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-style:italic;font-weight:400;line-height:120%">Confirming revenue guidance of at least 50% growth due to continued commercial momentum </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Company to Host Conference Call and Webcast today at 4&#58;30pm ET</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DENVER &#8211; August&#160;12, 2025 - TriSalus Life Sciences, Inc. (Nasdaq&#58; TLSI) (the &#8220;Company&#8221;), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June&#160;30, 2025, and provides an operation update. </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav&#174; product suite and proprietary PEDD&#174; platform across a broad range of solid tumor indications,&#8221; said Mary Szela, President and CEO of TriSalus. &#8220;We are pleased to reaffirm our full-year revenue growth guidance of 50%, reflecting increasing market penetration within liver-directed therapies. We will continue to invest in clinical data to extend the benefits of our PEDD technology platform to new embolization applications. With a strategic shift toward partnering development of Nelitolimod and an expanded focus on liver-directed therapies and new applications, we are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision&#8221;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2025 Highlights</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Generated $11.2 million in net sales, a 52% increase year-over-year, and sequential growth of 22% over the first quarter 2025.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Continued strong commercial momentum with expanded use of TriNav&#174; in liver embolization and continued to further develop new applications in new clinical settings focused on the interventional radiology specialty.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Expanded product portfolio with the successful launch of TriNav&#174; FLX, the latest advancement in Pressure-Enabled Drug Delivery (PEDD). Designed with a more flexible distal tip, TriNav FLX enhances navigability through tortuous vessels&#8212;providing an effective solution for physicians previously limited by anatomical barriers to PEDD adoption. Early market response has been strong, with sales surpassing internal projections.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Subsequent to the second quarter, the Company simplified its capital structure through the successful completion of an exchange offering of previously issued Series A Preferred stock.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2025 Financial Results </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Revenue, all from the sale of the TriNav system, was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.2 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended June 30, 2025</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, an increase of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> compared to the same period in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> and 22% sequential growth. Revenue growth was driven primarily by increased selling resources and increased market share. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gross margins were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> in the second quarter, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88%</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> in the same period of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">. The year-over-year decline was primarily driven by lower manufacturing efficiency associated with newly launched products, a dynamic we expect to improve as production scales and processes mature over the course of the year.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and Development (R&#38;D) expenses were approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.9 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.7 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same quarter of the prior year. The decline in R&#38;D costs is primarily a result of a decline in clinical trial costs relating to Nelitolimod. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Sales and Marketing (S&#38;M) expenses were approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.2 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> in the second quarter, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.0 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same quarter of the prior year. The year-over-year increase reflects continued investment in the expansion of our commercial organization.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">General &#38; Administrative (G&#38;A) expenses were approximately </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.7 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.0 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same quarter of the prior year. G&#38;A costs include non-cash stock-based compensation of $1.2 million and $0.7 million, respectively, for the same periods. The increase in G&#38;A costs is primarily a result of professional services related to legal services and audit. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Operating losses were </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.3 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, compared to Operating losses of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.2 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same period in 2024. Current reductions in operating losses are due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">Net loss attributable to common stockholders was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.0 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.1 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same period in 2024, primarily due to non-cash adjustments to the fair value of our contingent earnout liability. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:13.8pt">The basic and diluted loss per share was </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.27</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">, compared to </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> for the same period in 2024. </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%;padding-left:12.78pt">As of June 30, 2025, cash and cash equivalents totaled </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$26.5 million</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%"> providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026.</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-GAAP measure of adjusted EBITDA is reconciled in the table below as the Company believes it is an important measure of performance. Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024. Currently, reductions in adjusted EBITDA losses are due to increased sales, reduced research and development expenses and increased stock compensation in 2025. </font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will host a conference call and webcast today at 4&#58;30 PM eastern time to discuss its financial results for the quarter ended June&#160;30, 2025. Parties interested in participating by phone should register using this </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">online form</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. The event will also be webcast live on the </font><font style="color:#3051f2;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">investor relations section</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of TriSalus&#8217; website. A replay will also be available on the website following the event.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About TriSalus Life Sciences</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TriSalus Life Sciences</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is an oncology focused medical technology company seeking to transform outcomes for patients with solid tumors by integrating its innovative delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company&#8217;s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company&#8217;s two FDA-cleared devices use its proprietary Pressure-Enabled Drug Delivery&#8482; (PEDD) approach to deliver a range of therapeutics&#58; the TriNav&#174; Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. The PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company&#8217;s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-Oncology&#8482; (PERIO) clinical trials support the hypothesis that nelitolimod delivered via the PEDD technology may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by the PEDD technology are commonly present as well. The Company is in the final stages of data completion for a number of phase 1 clinical trials and will begin exploring partnership opportunities for development</font><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:5pt;margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward Looking Statements</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Statements </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">made in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward&#8208;looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company&#8217;s PEDD drug delivery technology, TriNav&#174; system and nelitolimod investigational immunotherapy,, and the Company&#8217;s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward&#8208;looking </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company&#8217;s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company&#8217;s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, made in this press release regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward&#8208;looking statements. Such statements include, but are not limited to, statements regarding the benefits and potential benefits of the Company&#8217;s PEDD drug delivery technology, TriNav&#174; system and nelitolimod investigational immunotherapy,, and the Company&#8217;s ability to execute on its strategy. Risks that could cause actual results to differ from those expressed in these forward&#8208;looking statements include risks associated with clinical development and regulatory approval of drug delivery and pharmaceutical product candidates, including that future clinical results may not be consistent with patient data generated during the Company&#8217;s clinical trials, the cost and timing of all development activities and clinical trials, unexpected safety and efficacy data observed during clinical studies, the risks associated with the credit facility, including the Company&#8217;s ability to remain in compliance with all its obligations thereunder to avoid an event of default, the risk that the Company will continue to raise capital through the issuance and sale of its equity securities to fund its operations, the risk that the Company will not be able to achieve the applicable revenue requirements to access additional financing under the credit facility, the risk that the Company will not become profitable on its expected timeline, if at all, the risk that the reported financial results will differ from the estimates provided in this press release, changes in expected or existing competition or market conditions, changes in the regulatory environment, unexpected litigation or other disputes, unexpected expensed costs, and other risks described in the Company&#8217;s filings with the Securities and Exchange Commission under the heading &#8220;Risk Factors.&#8221; All forward&#8208;looking statements contained in this press release speak only as of the date on which they were made and are based on management&#8217;s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law</font><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i2e400b2b03994483ad121dd14715ba19_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRISALUS LIFE SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited, in thousands)</font></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.583%"><tr><td style="width:1.0%"></td><td style="width:39.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.040%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Six Months Ended June 30,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,213&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,364&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,380&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,821&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cost of goods sold</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,802&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">912&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,883&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gross profit</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,411&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,452&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">17,083&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">11,938&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,923&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,666&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,219&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,510&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sales and marketing</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,163&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,004&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,897&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">12,691&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,657&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,956&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,628&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,583&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss from operations</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7,332)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,174)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(14,661)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,846)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other income (expense)&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">134&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">97&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">208&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">189&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,423)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(877)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2,632)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(880)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of SEPA, warrant, and revenue base redemption liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(330)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(9,016)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,165)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,495)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">700&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">13,689&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(120)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,701&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(40)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(44)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(291)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(197)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Loss before income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,291)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,325)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,661)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17,528)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax benefit (expense)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss available to common stockholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,288)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,332)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,663)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17,538)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Undeclared dividends on Series A preferred stock</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(714)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(801)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,426)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1,602)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss attributable to common stockholders</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(9,002)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5,133)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(20,089)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,140)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss per common share, basic and diluted</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.27)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.21)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.65)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(0.81)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Weighted average common shares outstanding, basic and diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,899,297&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,903,659&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">30,713,375&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,613,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRISALUS LIFE SCIENCES, INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited, in thousands)</font></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.805%"><tr><td style="width:1.0%"></td><td style="width:65.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.574%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.510%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">June 30, 2025</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">December 31, 2024</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Assets</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current assets&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cash and cash equivalents</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">26,490&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,525&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,571&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">5,087&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Inventory, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,807&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">4,048&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prepaid expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,009&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">38,084&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">20,669&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,711&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,669&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Right-of-use assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,210&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">419&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">423&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41,317&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,971&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Liabilities and Stockholders&#8217; Deficit</font></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Trade payables</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,902&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,078&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,355&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Short-term lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">123&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">216&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">221&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">383&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,324&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10,228&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term debt, net of unamortized discount and debt issuance costs</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">32,274&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">22,084&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Revenue base redemption liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">358&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">507&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Long-term lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,265&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,329&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Contingent earnout liability</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7,401&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Warrant and SEPA liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,997&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">8,316&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">60,740&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">49,865&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stockholders&#8217; deficit&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Preferred Stock, Convertible Series A, $0.0001 par value per share, $10.00 liquidation value per share. Authorized 10,000,000 shares at June&#160;30, 2025 and December&#160;31, 2024, respectively&#59; issued and outstanding, 3,594,002 and 3,985,002 shares at June&#160;30, 2025, and December&#160;31, 2024, respectively.</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Common stock, $0.0001 par value per share. Authorized 400,000,000 shares at June&#160;30, 2025 and December&#160;31, 2024, respectively&#59; issued and outstanding, 37,983,259 and 31,279,264 shares at June&#160;30, 2025, and December&#160;31, 2024, respectively.</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">278,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">253,652&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Accumulated deficit</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(298,212)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(279,549)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total stockholders&#8217; deficit</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(19,423)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(25,894)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Total liabilities and stockholders&#8217; deficit</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">41,317&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">23,971&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><font><br></font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><img alt="image.jpg" src="image.jpg" style="height:41px;margin-bottom:5pt;vertical-align:text-bottom;width:122px"></div></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Measure</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement the financial results presented in accordance with GAAP, TriSalus has also included in this press release non-GAAP adjusted EBITDA, which excludes from net loss, income tax expense, interest expense, interest income, change in fair value of SEPA, warrant and revenue-base redemption liabilities, change in fair value of contingent earn out liability, stock-based compensation expense and depreciation. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. TriSalus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand TriSalus&#8217; business.</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TriSalus believes that the presentation of these non-GAAP financial measures provides useful supplemental information to, and facilitates additional analysis by, investors. In particular, TriSalus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors&#8217; and analysts&#8217; ability to meaningfully compare TriSalus&#8217; results from period to period, and to identify operating trends in TriSalus&#8217; business.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Schedule of Non-GAAP Adjusted EBITDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited, in thousands)</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.910%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Three Months Ended June 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Six Months Ended June 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:125%">2024</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Net loss available to common stockholders</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(8,288)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(4,332)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(18,663)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17,538)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Income tax expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest income</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(134)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(97)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(208)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(189)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Interest expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,423&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">877&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,632&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Depreciation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">165&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">194&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">337&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">369&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">EBITDA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,837)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(3,351)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(15,900)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(16,468)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of warrant, SEPA, and revenue base redemption liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">330&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">9,016&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,165&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">6,495&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Change in fair value of contingent earnout liability</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(700)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(13,689)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">120&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(9,701)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Other expenses, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">291&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">197&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stock-based compensation</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,892&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">1,275&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">3,512&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2,361&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adjusted EBITDA</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(5,275)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(6,705)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(10,812)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(17,116)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contacts</font></div><div style="margin-top:8pt"><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For Media Inquiries&#58;</font><font style="color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br>Jeremy Feffer, Managing Director</font></div><div><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LifeSci Advisors</font></div><div><font style="background-color:#ffffff;color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">917.749.1494</font><font style="color:#1d2228;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="background-color:#ffffff;color:#0e32e1;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">jferrer&#64;lifesciadvisors.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For Investor Inquiries&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br>David Patience<br>Chief Financial Officer<br></font><font style="background-color:#ffffff;color:#0e32e1;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">investor.relations&#64;trisaluslifesci.com</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>tlsi-20250812.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:aedd4729-9990-4c3f-a3fb-d105919b6fed,g:4d950ad1-f782-4aff-baf4-8e324f289b63-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tlsi="http://trisaluslifesciences.com/20250812" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://trisaluslifesciences.com/20250812">
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tlsi-20250812_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tlsi-20250812_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tlsi-20250812_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://trisaluslifesciences.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>tlsi-20250812_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:aedd4729-9990-4c3f-a3fb-d105919b6fed,g:4d950ad1-f782-4aff-baf4-8e324f289b63-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://trisaluslifesciences.com/role/Cover" xlink:type="simple" xlink:href="tlsi-20250812.xsd#Cover"/>
  <link:definitionLink xlink:role="http://trisaluslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_42ca2108-6c2b-4eb5-94da-a33c0d85afd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:to="loc_us-gaap_ClassOfStockDomain_42ca2108-6c2b-4eb5-94da-a33c0d85afd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:to="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5377d773-1795-4be9-838f-de3f89f7439d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:to="loc_us-gaap_CommonStockMember_5377d773-1795-4be9-838f-de3f89f7439d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4a60e167-1327-4852-b729-ae3b233d2729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:to="loc_us-gaap_WarrantMember_4a60e167-1327-4852-b729-ae3b233d2729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b7b07aec-2bbb-4019-b997-7a22487a13f7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_DocumentType_b7b07aec-2bbb-4019-b997-7a22487a13f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_24e559a8-b9bd-418e-aa57-5f8785b0c596" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_DocumentPeriodEndDate_24e559a8-b9bd-418e-aa57-5f8785b0c596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4c2b436f-df30-464e-ace3-e2c5a1ad078a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityRegistrantName_4c2b436f-df30-464e-ace3-e2c5a1ad078a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0782d8ff-638e-4c29-8d6e-cb300a532e63" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0782d8ff-638e-4c29-8d6e-cb300a532e63" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_91112f70-0c9c-48a9-ab93-42f659585314" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityFileNumber_91112f70-0c9c-48a9-ab93-42f659585314" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_95d657a6-f848-4a8c-9733-7d21cec3a1df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityTaxIdentificationNumber_95d657a6-f848-4a8c-9733-7d21cec3a1df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0d7519d2-4cca-4595-afa5-be2ad45c7fce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressPostalZipCode_0d7519d2-4cca-4595-afa5-be2ad45c7fce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d50e3dab-3e8d-4588-9db1-4af09f8a272a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressStateOrProvince_d50e3dab-3e8d-4588-9db1-4af09f8a272a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_105d6f0e-4861-4920-b3fe-7021d89930ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressCityOrTown_105d6f0e-4861-4920-b3fe-7021d89930ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d74b1ea8-d1ba-45d8-b4f2-bbbde503fb6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressAddressLine1_d74b1ea8-d1ba-45d8-b4f2-bbbde503fb6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec18c1cb-8ac9-416f-89b3-cf30de0a9fad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_CityAreaCode_ec18c1cb-8ac9-416f-89b3-cf30de0a9fad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_06b57d60-0959-4752-82bf-1ac23641a73c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_LocalPhoneNumber_06b57d60-0959-4752-82bf-1ac23641a73c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2d2bef25-9afd-4937-8433-01afe7b1892c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_WrittenCommunications_2d2bef25-9afd-4937-8433-01afe7b1892c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ef9de1f1-2f2a-4e6d-abac-14f77c6a8557" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_SolicitingMaterial_ef9de1f1-2f2a-4e6d-abac-14f77c6a8557" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_448a6884-4aad-4257-b28f-456770a5f258" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_PreCommencementTenderOffer_448a6884-4aad-4257-b28f-456770a5f258" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1e800e83-d527-4ea0-84a3-77f8ba93f90e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1e800e83-d527-4ea0-84a3-77f8ba93f90e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e47755cd-ceb6-417f-96b0-f950020a9082" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_Security12bTitle_e47755cd-ceb6-417f-96b0-f950020a9082" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_76f2ff80-1237-4c2b-ac3f-711e81568996" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_TradingSymbol_76f2ff80-1237-4c2b-ac3f-711e81568996" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af72b9c8-e544-4e55-a6a6-f4021ce77eb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_SecurityExchangeName_af72b9c8-e544-4e55-a6a6-f4021ce77eb3" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bfb1a849-2536-419c-9856-00b70281f8f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityEmergingGrowthCompany_bfb1a849-2536-419c-9856-00b70281f8f0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f1d8bfa5-0444-42e5-b706-003b0072ad79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityExTransitionPeriod_f1d8bfa5-0444-42e5-b706-003b0072ad79" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b1cb82e-84f3-4ac0-bd04-000d493f3428" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityCentralIndexKey_5b1cb82e-84f3-4ac0-bd04-000d493f3428" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_39d20a72-1c5f-41b8-9de4-ccf73c0994e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_AmendmentFlag_39d20a72-1c5f-41b8-9de4-ccf73c0994e3" xlink:type="arc" order="22"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>tlsi-20250812_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:aedd4729-9990-4c3f-a3fb-d105919b6fed,g:4d950ad1-f782-4aff-baf4-8e324f289b63-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ClassOfStockDomain_f277c672-8637-4f7a-9b7f-862e617c0e4f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_afec759d-bd08-4413-8040-6f94dbcabe29_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_5c815dc0-c6cd-49d3-8495-3885a67b6718_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_112eb95d-c273-48c2-a146-e8940fb2b46c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_a83610f7-1229-4b51-aa2f-bf556d9c2cce_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_fb99da6c-86e5-4646-8706-31a236d8822f_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9ede52c8-f532-449c-9d48-816998b25620_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_984a73cc-c54f-458f-8405-711ffb989a3e_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_49081bcc-834b-4d97-927c-daca13ad6670_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5156f616-293f-4fbd-a1b4-e58afad68267_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_e9dbab7c-ff85-4496-be26-10fed92e40bf_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_f9575fd8-db56-4074-8361-4bd3bd9875b1_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1dbdd0b5-13db-479b-853f-c197a93a0953_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b15cc3bc-930f-4c0b-8221-851c1dfa322b_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_62641351-21ca-44b1-b2e8-fca7f87ac647_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_75439c32-2342-4619-aa6e-10442a276fa0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f094284d-589d-40d5-bab6-6f18dca17f95_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8c6d5e55-735e-48bf-b234-9b301597d84c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_20e86013-9961-4cf4-b368-f2a5f1188a42_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_873cee13-c00d-420b-9ad7-1e18eeadd5d0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f2b73c45-3cc1-4cc2-bd12-9bb67d3d2f36_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_7177daae-f364-419d-a745-b87d34005cb6_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_9ba0b269-84d6-446d-98ee-38f64dce7448_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bb7fc903-171d-4916-8983-26e67fcb456f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_87ff5e7c-9bc0-41c2-bf84-07d450e1045d_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bc8a95aa-8d33-44a5-8f6a-66fecdc07e7c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cb34e912-ea74-4095-aa5d-f1d425a2880a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8a30d59f-7f18-4253-b5e5-324de4e754d5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_db1622a9-14a5-42c3-b815-c6ae5451f4fa_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>tlsi-20250812_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:aedd4729-9990-4c3f-a3fb-d105919b6fed,g:4d950ad1-f782-4aff-baf4-8e324f289b63-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://trisaluslifesciences.com/role/Cover" xlink:type="simple" xlink:href="tlsi-20250812.xsd#Cover"/>
  <link:presentationLink xlink:role="http://trisaluslifesciences.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_93bc5238-b49f-4b16-a5ee-a05c3ed5df98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_93bc5238-b49f-4b16-a5ee-a05c3ed5df98" xlink:to="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_42ca2108-6c2b-4eb5-94da-a33c0d85afd1" xlink:to="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5377d773-1795-4be9-838f-de3f89f7439d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:to="loc_us-gaap_CommonStockMember_5377d773-1795-4be9-838f-de3f89f7439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4a60e167-1327-4852-b729-ae3b233d2729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a7b78063-e0ca-44a1-817b-69275733c1a7" xlink:to="loc_us-gaap_WarrantMember_4a60e167-1327-4852-b729-ae3b233d2729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_27dfc0bf-575a-4095-9c5d-c2faf41ed81f" xlink:to="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b7b07aec-2bbb-4019-b997-7a22487a13f7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_DocumentType_b7b07aec-2bbb-4019-b997-7a22487a13f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_24e559a8-b9bd-418e-aa57-5f8785b0c596" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_DocumentPeriodEndDate_24e559a8-b9bd-418e-aa57-5f8785b0c596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4c2b436f-df30-464e-ace3-e2c5a1ad078a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityRegistrantName_4c2b436f-df30-464e-ace3-e2c5a1ad078a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0782d8ff-638e-4c29-8d6e-cb300a532e63" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0782d8ff-638e-4c29-8d6e-cb300a532e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_91112f70-0c9c-48a9-ab93-42f659585314" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityFileNumber_91112f70-0c9c-48a9-ab93-42f659585314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_95d657a6-f848-4a8c-9733-7d21cec3a1df" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityTaxIdentificationNumber_95d657a6-f848-4a8c-9733-7d21cec3a1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0d7519d2-4cca-4595-afa5-be2ad45c7fce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressPostalZipCode_0d7519d2-4cca-4595-afa5-be2ad45c7fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d50e3dab-3e8d-4588-9db1-4af09f8a272a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressStateOrProvince_d50e3dab-3e8d-4588-9db1-4af09f8a272a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_105d6f0e-4861-4920-b3fe-7021d89930ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressCityOrTown_105d6f0e-4861-4920-b3fe-7021d89930ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d74b1ea8-d1ba-45d8-b4f2-bbbde503fb6e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityAddressAddressLine1_d74b1ea8-d1ba-45d8-b4f2-bbbde503fb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ec18c1cb-8ac9-416f-89b3-cf30de0a9fad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_CityAreaCode_ec18c1cb-8ac9-416f-89b3-cf30de0a9fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_06b57d60-0959-4752-82bf-1ac23641a73c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_LocalPhoneNumber_06b57d60-0959-4752-82bf-1ac23641a73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_2d2bef25-9afd-4937-8433-01afe7b1892c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_WrittenCommunications_2d2bef25-9afd-4937-8433-01afe7b1892c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_ef9de1f1-2f2a-4e6d-abac-14f77c6a8557" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_SolicitingMaterial_ef9de1f1-2f2a-4e6d-abac-14f77c6a8557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_448a6884-4aad-4257-b28f-456770a5f258" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_PreCommencementTenderOffer_448a6884-4aad-4257-b28f-456770a5f258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1e800e83-d527-4ea0-84a3-77f8ba93f90e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1e800e83-d527-4ea0-84a3-77f8ba93f90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e47755cd-ceb6-417f-96b0-f950020a9082" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_Security12bTitle_e47755cd-ceb6-417f-96b0-f950020a9082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_76f2ff80-1237-4c2b-ac3f-711e81568996" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_TradingSymbol_76f2ff80-1237-4c2b-ac3f-711e81568996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_af72b9c8-e544-4e55-a6a6-f4021ce77eb3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_SecurityExchangeName_af72b9c8-e544-4e55-a6a6-f4021ce77eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bfb1a849-2536-419c-9856-00b70281f8f0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityEmergingGrowthCompany_bfb1a849-2536-419c-9856-00b70281f8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_f1d8bfa5-0444-42e5-b706-003b0072ad79" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityExTransitionPeriod_f1d8bfa5-0444-42e5-b706-003b0072ad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5b1cb82e-84f3-4ac0-bd04-000d493f3428" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_EntityCentralIndexKey_5b1cb82e-84f3-4ac0-bd04-000d493f3428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_39d20a72-1c5f-41b8-9de4-ccf73c0994e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_57a896c4-6cf3-4788-8093-b718fe684c62" xlink:to="loc_dei_AmendmentFlag_39d20a72-1c5f-41b8-9de4-ccf73c0994e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image.jpg
<TEXT>
begin 644 image.jpg
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?!X<-X(3$P6$#_@_>"/!&M&W_(@    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 12,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">TRISALUS LIFE SCIENCES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-3009869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westminster<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6272 W 91st Ave<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">321-5212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0001826667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TLSI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TLSIW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tlsi-20250812.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trisaluslifesciences.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tlsi-20250812.htm">tlsi-20250812.htm</File>
    <File>tlsi-20250812.xsd</File>
    <File>tlsi-20250812_def.xml</File>
    <File>tlsi-20250812_lab.xml</File>
    <File>tlsi-20250812_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="26">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tlsi-20250812.htm": {
   "nsprefix": "tlsi",
   "nsuri": "http://trisaluslifesciences.com/20250812",
   "dts": {
    "inline": {
     "local": [
      "tlsi-20250812.htm"
     ]
    },
    "schema": {
     "local": [
      "tlsi-20250812.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tlsi-20250812_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tlsi-20250812_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tlsi-20250812_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 2,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 30,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 26
   },
   "report": {
    "R1": {
     "role": "http://trisaluslifesciences.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20250812.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tlsi-20250812.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant",
        "label": "Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://trisaluslifesciences.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001826667-25-000115-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001826667-25-000115-xbrl.zip
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M#<GLHOSO!2'=?2.DH/#VI/WWI_#JY-MH.1=&?(89#B95W%RW:64'*BZ(0'Q
ME,)L0#$F0"4' 2>7Y3>((9,D M\WS8/>D-UAD"FC['E0+C-R_C2$]7B8S68_
M8@@&%PK?27XO!A6))P-)72[!J(.A.,N09):>\T#1)C.W#Q=3E<CR:/4J!#B
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M>EUL\4 GXK4])[TERY&J]!E,K45X5)"?*&LP4_^@X)>@V>12 H\/(.Y417W
MT81[3+N1BN@!&Q:OR%ZOS.>I<2E?6FO]H7I4P9$,HF2FEO;D+C:JI(A6,+.G
M'-?K[M[=Z#7* *4?LV]U<I4)@?X>H$UEG&2[3[2,/6RZU-L.Y)V 9%',@!1;
M/V<V<CDCAD (.HYK?G07+G>(+L6JH,U"Y'>C0UY:AWQFJ:0RH2F@OI^EV->C
M]I>,QYB!1*,TB@)L_MY?#;FW;QM? 3^G57>JJTJL8LY<:8J97T/]OS(55R9Y
MO75 N2 3&F1L'EEB&#J4&H2*,,J +;EN C-:X*6U /J&X'AR3ZESCJ&VK_0"
M-K/+:NW^I-^NNYV3%7M8O%,]>:^,2#[36JLCD6Z](Q%P*9W6A58AX$:I3[&%
M&W]@?V<<E*A6K"G%AMR]\*C;KK?V;)OFC<!)IJNRX-9FX1V=ZKU<X*NJ=")6
M6:5) G1=_W;S[?UEGN]4&QU&-!C(/1 VK&O?VV[6+Q?U-=K7WR\OOY Q1/2R
M(#Q871=&ZF!:/1[(!*]<I7+Q^N"QWV&YN=@'"W_DX,M#%)#BL]@C-L8^<@I+
M*WP&= 'N'L-V[3JY7/IF,18%IZ4QSU(4=>D\+GO=GF<R'A6M8(IC,6!97O9J
MV%)H4%(;8TK$,0O]2](?7DS/*/A:#ZO$_6S16MHNO6\@-S-TSH1R!]X(=WI3
M= MSX+U\K_?=IKW>Y,LG@KOEF0!&!U=-;GCEB9?A)('T*?N#Z^0+W( MV[*1
MGTEF [KC]D?0-;&*EOM3$H\B4-C)*,H"Y*TA1VCTY)ATQ.]UH!IVRQFXSXY<
M95U]4 -JW^FYW,F+=[UZ%X6R6(S"O _# <H#BS S1"&6<I)H*EM 01J <P#"
MF5(>)(H]^BS?K2WI (J*9FE4&\XVQ;':&.Z6807EH=P@ @%%^#V/0 J,I6@6
M9N,^@$)Q^V6^;P444"+SGC$/50(5VR%3!8+<\]F? 2HW6^5[H:I%9578BX0N
M_J/23-0>E'T0O;C[6N[BZ5P@#L$RHS$!&.. 3A=13"= 2VFU-'[U_< L0:!V
MH:<Y<0YF"\5E'X/<]<,<5M:P,Q(Y[L;92,_*+.V''3L 94W-&(E5:]37%$^Q
M<J(87FUFVS%S2\QIKVDV4B/?(SEFODIOSO>BY],V$L:^ZX:<^1",V>[R^V=@
MJ-[K^;0.-6XCC":J<OG@V(Y:-*BM&]LA;WK4[ Z+A/,T+G8W>@$%<WM%OH%H
MU@+^'5L-/!:C^ND1.HRPL*I*5'2^!]_G ZF-4U(<"X*0%"!?G$M0\!BT%DGF
M8PUT;2U!CTY6I=(1^ GPT@!HB8J],'O"QRV,ZS E*UF%?:\I';)[$3)=#U5Z
M%Y$/[R]K7L"D]YO#A)MV$<<+@S#NW6 )KVQVW0N]SU(5H#&N*0SV*""U@,I$
MS8.9;PO2VSUOPD$F^SMNY2XA29810WX#[*-'A,X2SV^"=ZJ/:.:C>MK$%RK=
M8WSH*TM%!-SH,_(_+,3]FNL^$<\?4*]2B%N>UH"RM#R 9K;FXM0H"* 1;Q*8
M?#.GVN"IS1V&1BO+R3T-#4T1B-E7@*DSN146-_%)RLA5#S!V0K\#&X)#V8<+
M_#6;E";WNRX/N,'(2PXMD0%%LK  %8W(&2L)5SR2\R,F4B'4POVRN'?04M,M
M<I,71ZG>L5'H(=;Z8J9$ZL52R\+&QQF//CRCQP.P.4["L9:!W_19.9U#DED#
MJUZ*(S40EZB@6#CA(@H7QBSV<9,MCGN:,YF:S $0P!50*)ZN6A6!5+[Y? >P
MCG6U4&#_](S*7S2<<F[*W&/T54_WB@1^!>=4XN1&?J[VA];M!6'\>O/'FZ42
M5C(;'8)@C*8QPIEPK8D*.C,G-7QIPJF2IR4Y&(,_-*(33)M/P+U#/T@NG>D=
MSTD^2F9QQ6KG'X(4:,T$*F;(U%RE!:W][>/7GB0K!+VX?(!%3]_Q,,8']I[&
M;"[O8X:;7!?W2VL1G,]D65X$6AE54PJF4ICD0!3,$P3!@MY$.&;YF#!7O%*&
M)<4*>VZ5%=&>.^8E1MC;X*R00IDT&3: Y. J S7'2(^O248\+@R1X=KN%M(!
MZWR)/O6^#T4$0EO3;L5 _N]"_^;XKNMV7\#)>*R+VUIT<7>?>O@0"3DEZ&,4
M21?G%O2QG"6P_6285[NC0<DQ=?/%O502MB1 8[3"4I*X-E\8 .KNSR'01<VE
M2E,Y[P#5$LHHCCZ"!\!?DQ*$FUU4)DW/R1HHFM8"3=-DMNQ\ %=!&8T9#?4F
M>*D3! ?/E.&055"V4LX^\MSJ@**5OMNE)_N.G%ZO52>_,8^BGY1DWJCP*0E0
MDO7_TKMG!$^^*S''27 "0_Y4.;->FA7R/:A)E:^)"Y?^ &@CO7TZ2EA! >)T
M,1P*H#2:_+Y>.J[3[EZL(J!.;I? U'ZHI89$:>SFDR?2R"K>.Z?)P@0O:;MF
M5KXXV&N='9=:=Y-':RTZ?\H^Z%%;<WMTKX=K63,KL/SIV<0.G$0&!$YEM(ZP
MZMEA8(2^2CI)7O-DBDQ1=XE*,FTGB;26,HJW$K:!'J87N:*]R'L?)+HJF+GB
M6&I5FH_6*Q0$D.]!1C$<B/) 9(*-\(,E@9,2.Z+@M'O2=5937^1,GID3#:I)
M@:#D'>1AD,E=?;-/%U46:HV^S%DFF">5&4@ ,[[7D5TGHTN.D:53H8E:7<K'
M6EECJGUA[>A4*X4MJX_+KP%?5.YDE/65 4L5$N3V2.I-%8!1'WM$Y_ 5 FM
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MR6Z]$?.S0*KGF;V^7#0ZE5W)61;2#(2 ^9:RHU$&K_.3-Z4@EI[XW+64KC]
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MM.=#XW_I1_X4_C-*Q\&[_P]02P,$%     @ ;X ,6R^77=JY$   :7$  !$
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M*'[,-,+,=]C,H<5,XD7F%A^P'O@HAA3F"J':@(&W! C0S67+XSYS,\E2 @#
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MXP%'(^ZE9390I>T@O'U6]X#NX&!NP^7#X9X4OJPNRZISLBL>C\MET50WQV6
M&9KG0<=(T@33#L7BY!]2(-XEE%J9<$B3$5@_*F)OT(\7ZNU,2(9GPMLLA]^7
M75U@&&,\*DJH-Q[K HLE@4,_!8^I-%++A(D1L-]:W!O&.P9Q&Z@8#O3<7I\$
M=#.+V>JP:R-,AA2]3$G40A-AM2<&RT:B F<>?&)9&+9Y^JCYO4$]1GBWN<OA
MW%^%4$%=GY9U8_/_99>KX24HR4S@.+*TBP9,0&*CE<0!MT%(KZ+O.:KY8>A]
MMO>&^.# ;N-.1\/=32@?JM.J_)(5'F9!4DB"=20!C66C1%=-<*P]YZ<F:HMK
MNS'*M'[K^X9\2'"WH:O1H!_CRP_5>7E5S!C%<2=2+!UTBD(,I\0E$8BBG 5M
M3$+!C\?[UO"^H=XQI-N4]6B4U_]:1]DL*.$8X'(P,->.-P$7AB)R@HO_ )(F
MT:4C#N1W3>\;Z9W#NLW:#&'=9MRK"FPWG8!GVC/OB+;>X&H?EX;:N(2@GS0
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M=,0RUDG@2*6K[7O4<M5):[M$=1N%MI#O'J^MMT5>+U&7([N)$8PIGDI 4TT
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M(6QF],H^>O-B_4R^_(^RWKSX/U!+ P04    " !O@ Q;!JA &SP(  !)00
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M^/V1'BPQPB02021CDY;"QJEA^=&)[;(RME=_A&24Q#O R"=7UZYL[YR7+J/
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M2P$"% ,4    " !O@ Q;+Y==VKD0  !I<0  $0              @ $S*0
M=&QS:2TR,#(U,#@Q,BYH=&U02P$"% ,4    " !O@ Q;M_C%08L"  "1"
M$0              @ $;.@  =&QS:2TR,#(U,#@Q,BYX<V102P$"% ,4
M" !O@ Q;LM]NCHD(  !G/@  %0              @ '5/   =&QS:2TR,#(U
M,#@Q,E]D968N>&UL4$L! A0#%     @ ;X ,6W[:YWR3#   ^&P  !4
M         ( !D44  '1L<VDM,C R-3 X,3)?;&%B+GAM;%!+ 0(4 Q0    (
M &^ #%L&J$ ;/ @  $E!   5              "  5=2  !T;'-I+3(P,C4P
A.#$R7W!R92YX;6Q02P4&      8 !@". 0  QEH

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>tlsi-20250812_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tlsi-20250812.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826667</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-12</startDate>
            <endDate>2025-08-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0001826667</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-26">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-08-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">TRISALUS LIFE SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-39813</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">85-3009869</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">6272 W 91st Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Westminster</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">80031</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">(888)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">321-5212</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-18">TLSI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-20">Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-21">TLSIW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-24">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
